BioMarin Pharmaceutical (BMRN) Stock Price, Quote, News & History | Benzinga

SPY777.31+0.01%QQQ758.56+0.11%BTC/USD82,862.00−0.50%DIA510.84−0.04%GLD376.62+0.20%TLT77.04−0.14%

BioMarin Pharmaceutical Inc (BMRN) Stock Price, Quote, News & History

BMRNNASDAQ

Trade with Public

Trade with Public

$55.20

-1.02-1.81%

Last update: Oct 7, 7:56 PM

$55.55

-0.67-1.19%

OverviewNews Earnings Forecast Events Price Targets Financials Sentiment Ownership Compare Options Stock Report

Key Statistics

Open

$56.05

Close

$55.20

Volume / Avg.

2.08M / 1.99M

Day Range

$54.76 - $56.60

52 Wk Range

49.26 - 70.98

Market Cap

$10.74B

P/E Ratio

149.22

Dividend Yield

-

Exchange

NASDAQ

RSI

24

Short Interest

5.23%

Days to Cover

5.53

Recent BioMarin Pharmaceutical Inc. News

QUICK SPARK: Pharma Bro Martin Shkreli Says Ultragenyx Should Be M&A Target

Martin Shkreli calls Ultragenyx undervalued and a takeover target as the stock tanks after a trial failure.

Erica Kollmann

Crude Oil Gains Over 2%; US Dallas Fed Manufacturing Index Surges In August

U.S. stocks traded lower midway through trading, with the Nasdaq Composite falling more than 100 points on Monday.The Dow traded down 0.64% to 53,219.55 while the NASDAQ dipped 0.40% to 26,296.20. The S&P 500 also

Avi Kapoor

Ascendis Pharma, Science Applications International And Other Big Stocks Moving Higher On Monday

U.S. stocks were lower, with the Dow Jones index falling around 400 points on Monday. Shares of Ascendis Pharma A/S (NASDAQ:ASND) rose sharply on Monday. On Sunday, BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)

Avi Kapoor

Biomarin, Ascendis Reach Mutually Beneficial Agreement Ending Global Patent Disputes

BioMarin Pharmaceutical and Ascendis Pharma settled global patent disputes over Yuviwel, granting BioMarin significant royalty payments.

Vandana Singh

This Baidu Analyst Turns Bearish; Here Are Top 5 Downgrades For Wednesday

Wall Street analysts change outlook on top stocks, including BIDU and BMO. See their ratings and price targets on Benzinga's analyst page.

Avi Kapoor

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

857.09M

Investing Cash Flow (TTM)

-4.75B

Financing Cash Flow (TTM)

3.55B

Free Cash Flow (TTM)

725.08M

Capital Expenditure (TTM)

-132.01M

Net Change in Cash (TTM)

-340.14M

Analyst Trends and Forecast

7

3

May

1

Jul

7

3

Aug

1

1

Sep

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

3.7

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

$14.02B

PE Ratio (TTM)

149.22

PE Ratio (FWD)

8.34

PEG Ratio (TTM)

0.32

PS Ratio (TTM)

3.18

PB Ratio (TTM)

1.69

Earnings Yield % (TTM)

0.67%

Earnings Yield % (FWD)

11.99%

EV / EBITDA (TTM)

36.34

Price / EBITDA (TTM)

28.08

Price / Free Cash Flow (TTM)

14.94

Book Value / Share

$32.66

Company Debt

Total Debt

$4.19B

LT Debt

$3.53B

LT Debt Issuance (TTM)

-

LT Debt Repayment (TTM)

-

Total Cash

$874.01M

Debt to Equity

0.66

Issuance of Debt (TTM)

$3.65B

Repayment of Debt (TTM)

-